Product
HS-10241+ Almonertinib
1 clinical trial
1 indication
Indication
NSCLCClinical trial
A Phase 3, Randomized, Open-label, Multicenter Study to Assess the Efficacy and Safety of HS-10241 Combined With Almonertinib Versus Pemetrexed Combined With Platinum in Metastatic or Locally Advanced NSCLC With MET Amplification After Failure of the Prior EGFR -TKI TherapyStatus: Not yet recruiting, Estimated PCD: 2024-12-30